These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 15268625)

  • 1. Recent developments in target identification against hepatitis C virus.
    Brass V; Blum HE; Moradpour D
    Expert Opin Ther Targets; 2004 Aug; 8(4):295-307. PubMed ID: 15268625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Hepatitis C].
    Moradpour D; Blum HE
    Ther Umsch; 2004 Aug; 61(8):493-8. PubMed ID: 15457965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Therapy of hepatitis C].
    Moradpour D; Blum HE
    Praxis (Bern 1994); 2002 May; 91(22):977-82. PubMed ID: 12094432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis C: a concise review.
    Moradpour D; Wölk B; Cerny A; Heim MH; Blum HE
    Minerva Med; 2001 Oct; 92(5):329-39. PubMed ID: 11675577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus.
    Lamarre D; Anderson PC; Bailey M; Beaulieu P; Bolger G; Bonneau P; Bös M; Cameron DR; Cartier M; Cordingley MG; Faucher AM; Goudreau N; Kawai SH; Kukolj G; Lagacé L; LaPlante SR; Narjes H; Poupart MA; Rancourt J; Sentjens RE; St George R; Simoneau B; Steinmann G; Thibeault D; Tsantrizos YS; Weldon SM; Yong CL; Llinàs-Brunet M
    Nature; 2003 Nov; 426(6963):186-9. PubMed ID: 14578911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serine protease inhibitors as anti-hepatitis C virus agents.
    Reiser M; Timm J
    Expert Rev Anti Infect Ther; 2009 Jun; 7(5):537-47. PubMed ID: 19485794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis C: molecular virology and antiviral targets.
    Moradpour D; Brass V; Gosert R; Wölk B; Blum HE
    Trends Mol Med; 2002 Oct; 8(10):476-82. PubMed ID: 12383770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Portulaca oleracea L. as a Prospective Candidate Inhibitor of Hepatitis C Virus NS3 Serine Protease.
    Noreen S; Hussain I; Tariq MI; Ijaz B; Iqbal S; Qamar-ul-Zaman ; Ashfaq UA; Husnain T
    Viral Immunol; 2015 Jun; 28(5):282-9. PubMed ID: 25871297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of chronic hepatitis C patients with the NS3/4A protease inhibitor danoprevir (ITMN-191/RG7227) leads to robust reductions in viral RNA: a phase 1b multiple ascending dose study.
    Forestier N; Larrey D; Guyader D; Marcellin P; Rouzier R; Patat A; Smith P; Bradford W; Porter S; Blatt L; Seiwert SD; Zeuzem S
    J Hepatol; 2011 Jun; 54(6):1130-6. PubMed ID: 21145848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Virology: fresh assault on hepatitis C.
    Rice CM
    Nature; 2003 Nov; 426(6963):129-31. PubMed ID: 14578912
    [No Abstract]   [Full Text] [Related]  

  • 11. Hepatitis C virus virology and new treatment targets.
    Meier V; Ramadori G
    Expert Rev Anti Infect Ther; 2009 Apr; 7(3):329-50. PubMed ID: 19344246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of small-molecule inhibitors of HCV NS3-4A protease as potential therapeutic agents against HCV infection.
    Chen SH; Tan SL
    Curr Med Chem; 2005; 12(20):2317-42. PubMed ID: 16181135
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent developments in the discovery of hepatitis C virus serine protease inhibitors--towards a new class of antiviral agents?
    Narjes F; Koch U; Steinkühler C
    Expert Opin Investig Drugs; 2003 Feb; 12(2):153-63. PubMed ID: 12556211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Telaprevir: a new hope in the treatment of chronic hepatitis C?
    Fowell AJ; Nash KL
    Adv Ther; 2010 Aug; 27(8):512-22. PubMed ID: 20652658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effectiveness and safety of direct-acting antiviral agents for treatment of patients with chronic hepatitis C virus infection].
    Yang J; Rao HY
    Zhonghua Gan Zang Bing Za Zhi; 2018 Mar; 26(3):175-178. PubMed ID: 29804389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase III results of Boceprevir in treatment naïve patients with chronic hepatitis C genotype 1.
    Manns MP; Markova AA; Calle Serrano B; Cornberg M
    Liver Int; 2012 Feb; 32 Suppl 1():27-31. PubMed ID: 22212568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Future treatment of chronic hepatitis C with direct acting antivirals: is resistance important?
    Halfon P; Sarrazin C
    Liver Int; 2012 Feb; 32 Suppl 1():79-87. PubMed ID: 22212577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current and evolving therapies for hepatitis C.
    Moradpour D; Blum HE
    Eur J Gastroenterol Hepatol; 1999 Nov; 11(11):1199-202. PubMed ID: 10563526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Editorial: Towards the eradication of hepatitis C virus.
    Marcellin P; Asselah T
    Liver Int; 2012 Feb; 32 Suppl 1():1. PubMed ID: 22212564
    [No Abstract]   [Full Text] [Related]  

  • 20. HCV protease inhibitors bring new options for patients.
    Traynor K
    Am J Health Syst Pharm; 2011 Aug; 68(15):1372, 1374, 1379. PubMed ID: 21785015
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.